Financial News
Articles published by Natera, Inc.
![](https://mms.businesswire.com/media/20240118279116/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
![](https://mms.businesswire.com/media/20240116910268/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Provides Update on Ravgen Trial
January 16, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20240109561596/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
![](https://mms.businesswire.com/media/20231228439015/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
![](https://mms.businesswire.com/media/20231227389284/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
December 27, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20231221683887/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
December 21, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20231211868061/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
![](https://mms.businesswire.com/media/20231206078253/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
December 06, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20231114680976/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Announces Real-World Data Collaboration with Merck
November 14, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20231108253620/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Reports Third Quarter 2023 Financial Results
November 08, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20231107253448/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
November 08, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20231107462455/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera to Participate in November Investor Conferences
November 07, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20231102763643/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
![](https://mms.businesswire.com/media/20231022276686/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
![](https://mms.businesswire.com/media/20231020638373/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera to Report its Third Quarter 2023 Results on November 8
October 20, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20231019370305/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
October 19, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20231016308600/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
October 16, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20231004918931/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
![](https://mms.businesswire.com/media/20231003906151/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
![](https://mms.businesswire.com/media/20231002107347/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Submits First PMA Module to the FDA for Signatera™
October 02, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20230918726010/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Announces Senior Leadership Appointments
September 18, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20230913435380/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
September 14, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20230906728529/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Announces Pricing of $250 Million Follow-On Offering
September 07, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20230906591286/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Launches Proposed Follow-On Offering
September 06, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20230901916970/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera to Participate in Upcoming Investor Conferences
September 01, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20230816491383/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
![](https://mms.businesswire.com/media/20230803772059/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Natera Reports Second Quarter 2023 Financial Results
August 03, 2023
From Natera, Inc.
Via Business Wire
Tickers
NTRA
![](https://mms.businesswire.com/media/20230801498467/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
![](https://mms.businesswire.com/media/20230731657407/en/1736351/22/Natera_floret_Logo_%281%29.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.